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triple-marker cardiac MRi detects 
sequential tissue changes of 
healing myocardium after a 
hydrogel-based therapy
Maaike van den Boomen  1,2,3, Hanne B. Kause4, Hans C. van Assen4, Patricia Y. W. Dankers5,6, 
Carlijn V. C. Bouten1,5 & Katrien Vandoorne1*
Regenerative therapies based on injectable biomaterials, hold an unparalleled potential for treating 
myocardial ischemia. Yet, noninvasive evaluation of their efficacy has been lagging behind. Here, we 
report the development and longitudinal application of multiparametric cardiac magnetic resonance 
imaging (MRI) to evaluate a hydrogel-based cardiac regenerative therapy. A pH-switchable hydrogel 
was loaded with slow releasing insulin growth factor 1 and vascular endothelial growth factor, 
followed by intramyocardial injection in a mouse model of ischemia reperfusion injury. Longitudinal 
cardiac MRI assessed three hallmarks of cardiac regeneration: angiogenesis, resolution of fibrosis 
and (re)muscularization after infarction. The multiparametric approach contained dynamic contrast 
enhanced MRi that measured improved vessel features by assessing fractional blood volume and 
permeability*surface area product, T1-mapping that displayed reduced fibrosis, and tagging MRI that 
showed improved regional myocardial strain in hydrogel treated infarcts. Finally, standard volumetric 
MRI demonstrated improved left ventricular functioning in hydrogel treated mice followed over time. 
Histology confirmed MR-based vessel features and fibrotic measurements. Our novel triple-marker 
strategy enabled detection of ameliorated regeneration in hydrogel treated hearts highlighting the 
translational potential of these longitudinal MRI approaches.
Cardiovascular diseases, including myocardial infarction (MI), remain the leading cause of mortality across the 
world1. MI is caused by an occlusion of a coronary artery, resulting in cardiomyocyte cell death due to insufficient 
nutrient and oxygen supply. This primary injury provokes a cascade of events that eventually could lead to cardiac 
remodeling and heart failure. Firstly, local cell death induces the inflammatory phase of infarct healing, starting 
shortly after the MI. Blood vessels become permeable allowing inflammatory cells to clean the wound of dead 
cells and debris2. Secondly, the proliferative phase begins several days after MI. Activated myofibroblasts pro-
duce extracellular matrix proteins accompanied by angiogenesis at the infarct borders. Finally, during maturation 
phase a collagen-rich scar is formed, replacing viable myocardium and stabilizing the ventricular wall. Because 
of the loss of healthy cardiomyocytes by scar formation, the non-ischemic remote myocardium undergoes hyper-
trophy to compensate for the reduced contractile force development after acute MI. Chronically, adverse cardiac 
remodeling deteriorates cardiac function resulting in heart failure development3.
Several regenerative approaches attempting to improve outcome or even regenerate the damaged heart after 
MI, are still in their infancy. Highly promising strategies to regenerate viable myocardium by grafting or activat-
ing stem and/or progenitor cells or by re-entering cardiac myocytes into the cell cycle are still an unfulfilled ambi-
tion4. Transplantation of adult stem cells improve short-term cardiac function post-MI, yet excreted paracrine 
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factors, such as vascular endothelial growth factor (VEGF) and insulin growth factor 1 (IGF1) account for this 
therapeutic improvement4. VEGF is a cytokine involved in the formation of new blood vessels or angiogenesis5. 
IGF1 is a key regulator of cell proliferation and survival, differentiation, and metabolism with cardioprotective 
properties6–8.
A promising regenerative strategy involves the application of biomaterials as scaffolds that can stimulate repair 
and regeneration9,10. Injectable hydrogels have been proposed and tested to deliver biological agents post-MI11,12. 
The use of hydrogels could create a three-dimensional (3D) matrix, resembling the endogenous extracellular 
matrix11 and sustained delivery of entrapped growth factors13. Here, we used a hydrogel based on supramolecular 
ureido-pyrimidinone (UPy) moieties coupled to poly(ethylene glycol) chains (UPy-hydrogel) loaded with VEGF 
and IGF1 (UPyGF-hydrogel). Previously, we showed that a local catheter injection of this UPy-hydrogel into por-
cine hearts after MI allowed local release of hepatocyte growth factor (HGF) and IGF1 reducing the size of the 
infarct scar14. The transient network of the UPy-hydrogel was shown to be pH-responsive, which enables injec-
tion in the solution state at basic pH followed by formation of a transient network at neutral tissue pH. Rheology 
and viscosity measurements of the UPy-hydrogel have been previously described14. Additionally, we recently 
demonstrated the successful in vivo identification of an injected UPy-hydrogel based on a UPy-unit modified 
with gadolinium (Gd) complex by magnetic resonance imaging (MRI)15. In the present study an UPyGF-hydrogel 
was locally injected to deliver VEGF and IGF1 in order to promote tissue repair to improve outcome after MI5,7.
Cardiac MRI is a powerful translational technology16 that could improve the assessment of cardiac healing 
aspects of novel regenerative treatments. Each novel cardiac regenerative therapy changes the complex spatial 
and temporal tissue dynamics of infarct healing after MI. Yet, in vivo cardiac imaging methods to serially eval-
uate these tissue changes with respect to the efficacy of novel regenerative treatments, are still an unmet need17. 
Cardiac MRI has previously reported on each of these hallmarks of interest separately18. First, albumin-based 
dynamic contrast enhanced (DCE) MRI allows noninvasive assessment of vascular density and permeability, 
which are both vessel features that could indicate angiogenesis19,20. Second, mapping T1 relaxation times supports 
in vivo evaluation of fibrosis21,22. Lastly, tagging MRI to measure strain, indicates local (re)muscularization23.
The novelty of this study is the combinatorial assessment of three hallmarks of regeneration in one single 
MRI session, namely angiogenesis, resolution of fibrosis and remuscularization simultaneously18. This integrated 
approach offers tremendous benefits by assessing dynamic cardiac regeneration and remodeling processes at high 
spatial and temporal resolution. We envision that such multiparametric platforms will enable simultaneous non-
invasive studies of novel regenerative cardiac therapies by evaluating cardiac hallmarks in the clinics, which gives 
improved insights about the efficacy those therapies. To evaluate this triple-marker approach, we noninvasively 
assessed a novel local cardiac treatment of a UPyGF-hydrogel in a murine ischemia reperfusion (I/R) injury model, 
which is expected to alter each of these biomarkers based on each of their independent regenerative capacities.
Results
UpyGf-hydrogel specifications and tracking. In vitro release of IGF1 was sustained from the UPyGF-
hydrogel for the first 7 days until 84 ± 5%, and the release of VEGF approached 33 ± 1% after 7 days (Fig. 1a). 
This indicated that incorporation of these growth factors in the UPyGF-hydrogel enabled a sustained release for 
the active phases of cardiac repair3. The UPyGF-hydrogel loaded with IGF1 and VEGF was intramyocardially 
injected at two locations at the border of the ischemic area 2 min before reperfusion (Fig. 1b). In order to verify 
its intramyocardial localization, the UPyGF-hydrogel was loaded with ultrasmall superparamagnetic iron oxide 
(USPIO). During I/R injury, USPIO-loaded UPyGF-hydrogel was locally injected at the border zone. Ex vivo T2*-
weighted MR imaging of isolated hearts successfully identified the two injection sites (Fig. 1c).
implementation of in vivo triple-marker cardiac MRI in healthy hearts. The hallmarks of cardiac 
repair were assessed in vivo before and at several timepoints after I/R injury by MRI as shown in the study outline 
(Fig. 1d). Firstly, to quantify vascular repair processes, intravenous injection of paramagnetically-labeled albu-
min was followed by DCE MRI (Fig. 2a,b). Cardiac MRI-derived parametric maps confirmed healthy myocar-
dial fractional blood volume (fBV) of 0.10 ± 0.01, a measure for microvascular density and permeability*surface 
area product (PS) of 0.0014 ± 0.0004 min−1, detecting endothelial barrier function (Fig. 2a)19,20. The fBV was 
calculated from the initial enhancement by the macromolecular albumin immediately after injection (intercept 
with the y-axis), when albumin was confined to the blood vessels. The PS was derived from the rate of change in 
contrast concentration in the myocardium with time (Fig. 2b). Secondly, the degree of myocardial fibrosis was 
measured by mapping T1 relaxation times from pre-contrast signal intensities at variable flip angles of cardiac 
MRI. Mean T1 value of healthy myocardium measured 1.541 ± 0.030 s (Fig. 2c,d), which is similar to previously 
published data19,24. Thirdly, tagging MRI was performed with local spatial tag frequency estimation to analyze 
regional myocardial function23,25 to determine changes in the peak myocardial strain (Fig. 2e; Supplementary 
Movie 1). Healthy peak strains in the myocardium were for 9.1 ± 0.8% for radial strain (Err) and −12.8 ± 1.4% 
for circumferential strain (Ecc) (Fig. 2f,g).
DCE MRI reveals improved angiogenesis in hydrogel treated infarcts. At day 1 after I/R, GdDTPA 
was intravenously injected to verify infarct size by late gadolinium enhanced (LGE) MRI (Fig. 3a). Serially at day 3 
and 22 after I/R, macromolecular GdDTPA-albumin-RhoB was administered to characterize vascular parameters 
fBV (Fig. 3b) and PS (Fig. 3c). LGE MRI showed a small infarct size for saline (12.4 ± 1.2%) and UPyGF-hydrogel 
(11.1 ± 1.1%) treated mice (Fig. 3d) similar to previously published data26,27. This I/R injury model is clinically 
very relevant27,28 and the similar infarct size allowed further comparison of consequent cardiac repair.
To follow the effect of slow releasing IGF1 and VEGF from the UPyGF-hydrogel at the border zone of the 
infarcted myocardium, vascular features were followed by albumin-based DCE MRI. Longitudinal follow-up 
showed an increase of fBV at day 3 (0.17 ± 0.02) and at day 22 (0.21 ± 0.01) in the reperfused myocardium 
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treated with the UPyGF-hydrogel compared to healthy myocardium (0.11 ± 0.01). The increase of fBV was 
not significantly different at day 3 (0.14 ± 0.03) and at day 22 (0.12 ± 0.04) after I/R in the saline treated rep-
erfused myocardium compared to healthy myocardium (Fig. 3e). Furthermore, the endothelial barrier func-
tion was analyzed. The PS values in the infarcted area at day 3 in saline-treated (4.2 ± 0.9 × 10–3min−1) and 
UPyGF-hydrogel treated (3.6 ± 1.1 × 10–3min−1; P = 0.0593) appeared higher than healthy PS values, but were not 
significantly different from healthy myocardium. Additionally at day 22, PS values of saline-treated reperfused 
myocardium (3.6 ± 1.4 × 10–3min−1) remained similar to the healthy myocardium. Only at day 22 after I/R a 
significant increase of PS was demonstrated in the UPyGF-hydrogel treated (6.6 ± 1.7 × 10–3min−1) compared 
to healthy myocardium (Fig. 3f). This indicated improved vascular density and enhanced angiogenesis at the 
UPyGF-hydrogel treated infarcts.
t1-mapping demonstrates mitigated cardiac fibrosis in hydrogel treated infarcts. Fibrosis 
is inherent to scar tissue formation and the fibrotic response of the tissue may be altered by UPyGF-hydrogel 
injection after I/R. At day 3 post-infarction, T1 values of both saline (2.172 ± 0.008 s) and UPyGF-hydrogel 
(1.780 ± 0.083 s) injected ischemic myocardium were increased compared to T1 values of healthy myocar-
dium (1.541 ± 0.030 s) but only the saline group was significantly different (Fig. 4a,b). At day 22 after I/R, the 
Figure 1. UPyGF-hydrogel characterization and in vivo setup. (a) In vitro release of IGF1/VEGF embedded in 
the UPyGF-hydrogel by daily collection of medium at 37 °C over one week (mean ± s.e.m, n = 4 measurements). 
(b) Localization of intramyocardial delivery of UPyGF-hydrogel 2 min before reperfusion in a mouse model of 
myocardial ischemia reperfusion (I/R). pH-switchable UPyGF-hydrogel loaded with insulin-like growth factor 
1 (IGF1) and vascular endothelial growth factor (VEGF) in a solution state during basic conditions. After local 
injection, the UPyGF-hydrogel slowly released insulin-like growth factor 1 (IGF1) and vascular endothelial 
growth factor (VEGF). (c) Proof-of-concept ex vivo T2* MRI to verify intramyocardial UPyGF-hydrogel 
injections (arrows) labeled with ultrasmall superparamagnetic iron oxide at an infarcted heart 30 min after I/R. 
(d) In vivo experimental set-up of serial cardiac magnetic resonance imaging (MRI) and histology of hearts 
before and after I/R. The illustration of the heart (1b) and the mouse (1d) were modified from Servier Medical 
Art (http://smart.servier.com/), licensed under a Creative Common Attribution 3.0 Generic License.
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saline-injected infarcts still demonstrated a significantly increased T1 (2.077 ± 0.075 s), indicating increased fibro-
sis. At day 22 after I/R, T1 values of UPyGF-hydrogel treated infarcts (1.724 ± 0.123 s) did not increase further 
and remained non-significantly different from healthy myocardium (Fig. 4a,b). This suggests reduced fibrosis in 
infarct treated with UPyGF-hydrogel.
Figure 2. Noninvasive multiparametric cardiac MRI of healthy murine hearts. (a) Postcontrast parametric 
maps of fractional blood volume (fBV) and permeability*surface area product (PS) calculated from albumin-
based dynamic contrast-enhanced MRI in hearts of healthy mice. (b) Contrast agent accumulation in the 
consecutive MR images for fBV (intercept at time 0) and PS (=slope) in control (n = 14). (c) Pixel-based 
parametric T1 map of a healthy heart. (d) Flip angle based signal intensities to calculate T1 cardiac maps 
(n = 14). (e) Tagging MR images of the healthy heart during diastole and systole. (f) Parametric maps of 
circumferential strain (Ecc) and radial strain (Err). (g) Individual values of circumferential and radial strain for 
8 different cardiac phases (n = 13). Each dot represents an individual mouse; bars represent mean ± s.e.m.
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Tagging MRI shows enhanced regional myocardial strain in hydrogel treated hearts. As the 
UPyGF-hydrogel could possibly affect preservation of regional contractility of the heart, Err and Ecc were longitu-
dinally assessed on day 1, day 3 and day 22 after I/R (Fig. 5a). For saline injected hearts, midventricular peak Err 
at day 1 (4.2 ± 1.1%), day 3 (4.0 ± 0.3%) and at day 22 (4.2 ± 0.8%) appeared reduced. Yet only at day 3 and day 22 
this decrease was significant compared to the Err of healthy myocardium (9.1 ± 0.8%). For the UPyGF-hydrogel 
treated hearts, midventricular peak Err at day 1 (3.5 ± 1.0%), day 3 (5.3 ± 1.7%) and day 22 (5.9 ± 0.5%) appeared 
Figure 3. Serial contrast-enhanced cardiac MRI shows altered vascular features during cardiac repair in UPyGF-
hydrogel injected infarcts. (a) Late gadolinium enhanced (LGE) MRI with arrows showing the infarct day 1 
post-MI. (b) Postcontrast parametric maps of fractional blood volume (fBV) and (c) permeability*surface 
area product (PS) calculated from albumin-based dynamic contrast-enhanced MRI. (d) Infarct size one day 
after I/R. (e) Mean fBV and, (f) mean PS in healthy myocardium and in saline and UPyGF-hydrogel injected 
infarcts day 3 and day 22 post-infarction. Each dot represents an individual mouse; healthy mice (n = 20), saline 
injected mice (n = 11, day 1; n = 7, day 3; n = 4, day 22), UPyGF injected mice (n = 9. day 1; n = 8, day 3; n = 7, 
day 22); bars represent mean ± s.e.m; Mann-Whitney U test; *P < 0.05, **P < 0.01.
Figure 4. Longitudinal T1 mapping uncovers reduced fibrosis throughout cardiac healing in UPyGF-hydrogel 
injected infarcts. (a) Longitudinal T1 mapping of healthy hearts and hearts after I/R injected with saline or 
UPyGF-hydrogel. (b) T1 values. Each dot represents an individual mouse; n = 20 for healthy, healthy mice 
(n = 20), saline injected mice (n = 7, day 3; n = 4 day 22), UPyGF injected mice (n = 8, day 3; n = 7, day 22); bars 
represent mean ± s.e.m.; Mann-Whitney U test; **P < 0.01; *** P < 0.001.
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not significantly decreased compared to Err of healthy myocardium (Fig. 5a,b), indicating improved regional 
strain. Furthermore, the Ecc of saline injected hearts was declined at all timepoints after I/R (day 1: −4.3 ± 2.4%; 
day 3: −1.3 ± 0.5%; day 22: −1.0 ± 0.7%), and significantly different from Ecc of healthy myocardium prior to 
MI (−12.8 ± 1.4%). For the UPyGF-hydrogel treated hearts, Ecc was significantly reduced at day 3 (−4.1 ± 3.2%) 
compared to Ecc of healthy hearts. Ecc of UPyGF-hydrogel injected hearts appeared at day 1 (−10.1 ± 2.5%) and 
day 22 (−9.0 ± 1.0) after I/R, similar to healthy myocardium prior to MI (Fig. 5a,b; Supplementary Movie 2,3). 
These data clearly indicated that the UPyGF-hydrogel preserved myocardial strain values, suggesting a protective 
effect on muscular deformation during cardiac remodeling.
Left ventricular function improves in hydrogel treated heart after MI. Survival rates for the saline 
and UPyGF-hydrogel treated mice were found not significantly different, however a trend towards improved sur-
vival in the UPyGF-hydrogel treated mice was observed; 77.7% of the initial UPyGF-hydrogel treated group sur-
vived, while 36.4% of the initial saline treated group survived (Mantel-Cox analysis p = 0.19, Fig. 6a). In addition 
to overall survival, LV global function was evaluated by calculation of the ejection fraction (EF) from cine MRI. 
The mean healthy EF was determined from healthy hearts (51.7 ± 1.5%). After I/R, the EF in saline injected hearts 
appeared significantly reduced after I/R (day 3: 41.7 ± 3.5%; day 22: 38.0 ± 6.0%). In UPyGF-hydrogel-treated 
hearts post-infarction EF remained similar (day 3: 49.3 ± 3.8%; day 22: 50.5 ± 5.1%) to the EF of healthy hearts 
(Fig. 6b,c). In healthy hearts LV end-diastolic volume (LVEDV; 80.0 ± 3.3 μL) and end-systolic volume (LVESV; 
38.1 ± 1.8 μL) were measured. After infarction, the LVEDV in saline injected day 3: 87.1 ± 4.4 μL; day 22: 
94.0 ± 8.3 μL) and UPyGF-hydrogel-treated (day 3: 85.3 ± 4.2 μL; day 22: 89.1 ± 2.3 μL) hearts appeared not sig-
nificantly elevated (Fig. 6d). The post-infarction LVESV in saline injected hearts appeared significantly elevated 
after I/R (day 3: 50.6 ± 3.6 μL; day 22: 56.0 ± 3.6 μL). Yet in UPyGF-hydrogel-treated hearts post-infarction LVESV 
remained similar (day 3: 44.8 ± 4.32 μL; day 22: 46.99 ± 4.6 μL) to the LVESV of healthy hearts (Fig. 6e). We con-
cluded that infarcted hearts treated with UPyGF-hydrogel were able to maintain its LV cardiac function after I/R, 
despite the tissue changes.
Histology confirms the tissue changes detected by multiparametric cardiac MRI. Microscopic 
evidence of reduced collagen content by picrosirius red staining is shown in UPyGF-hydrogel treated hearts 
22 days after I/R (Fig. 7a). Collagen content of each group, namely healthy hearts (1.93 ± 0.7%), saline treated 
Figure 5. UPyGF-hydrogel injection maintains cardiac strain as assessed by serial tagging MRI. (a) Longitudinal 
assessment of circumferential strain (Ecc), and radial strain (Err) for healthy hearts and infarcted hearts on day 
1, 3 and 22 after I/R injected with saline or UPyGF-hydrogel. (b) Ecc and Err values for healthy myocardium 
and infarcts. Each dot represents an individual mouse; healthy mice (n = 13), saline injected mice (n = 4, day 
1; n = 5, day 3; n = 3, day 22), UPyGF injected mice (n = 4, day 1; n = 4, day 3; n = 3, day 22); bars represent 
mean ± s.e.m.; Mann-Whitney U test; *P < 0.05, **P < 0.01 compared to healthy values.
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(14.8 ± 1.2%) and UPyGF-hydrogel (11.7 ± 0.5%) treated hearts 22 days after I/R, was significantly different 
(Fig. 7c). Cardiac MRI T1 values correlated strongly with values of collagen content (R2 = 0.6980; P = 0.0018), 
confirming T1 mapping is a reliable approach to assess myocardial fibrosis after MI (Fig. 7d). Vascular features 
were assessed in histology by comparing early (FITC-albumin) with late (GdDTPA-albumin-RhoB) albumin 
localization. Fluorescence microscopy showed enhanced angiogenesis displayed by higher albumin signal at 
early and late time points in UPyGF-hydrogel treated myocardium 22 days postinfarct (Fig. 7b). The area fraction 
of early albumin, which is a measure for vascular density, was significantly increased for the UPyGF-hydrogel 
treated hearts (10.8 ± 0.8%) compared to healthy (7.4 ± 0.4%) and saline injected (8.9 ± 0.6%) hearts (Fig. 7e). 
As MR-based fBV is also calculated from an early albumin time point, fBV correlated well with early fluorescent 
FITC-albumin, (R2 = 0.4242, P < 0.0001; Fig. 7f). Subtraction of the early FITC-albumin area from the late extrav-
asated GdDTPA-albumin-RhoB revealed the amount of extravasated albumin. For healthy myocardium only 
0.5 ± 0.1% extravasated. The % area extravasated albumin for saline treated myocardium (11.5 ± 1.4%) was sig-
nificantly higher compared to extravasation in healthy myocardium. Extravasation of albumin in UPyGF-hydrogel 
treated myocardium (23.3 ± 3.7%) was significantly increased compared with extravasation in healthy and saline 
injected myocardium (Fig. 7g). These histology-based findings were in positive correlation with the MR-based 
PS (R2 = 0.5751, P < 0.0001). To conclude, these findings confirmed the MR-based results for day 22, displaying 
reduced fibrosis and enhanced revascularization in the UPyGF-hydrogel treated group.
Figure 6. Cardiac cine MRI reveals reduced LV remodeling after I/R injected with UPyGF-hydrogel. (a) Survival 
of Saline and UPyGF-hydrogel injected mice after ischemia reperfusion injury of the heart (Kaplan-Meier 
survival curve). (b) Ejection fraction. (c) End-diastolic and end-systolic long axis MR images of hearts on day 
22 after I/R injected with saline or UPyGF-hydrogel. (d) Left ventricular end-diastolic volume (LVEDV). (e) 
Left ventricular end-systolic volume (LVESV). Each dot represents an individual mouse; healthy mice (n = 20), 
saline injected mice (n = 7, day 3; n = 4, day 22), UPyGF injected mice (n = 8, day 3; n = 7, day 22); bars represent 
mean ± s.e.m.; Mann-Whitney U test; **P < 0.01.
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Figure 7. Histological validation of cardiac MRI data for infarcted hearts 22 days after I/R injected with UPyGF-
hydrogel. (a) Representative images of picrosirius red for collagen. (b) Green fluorescence staining showing 
albumin-GFP injected at t = 4 min before euthanasia showing microvascular density and GdDTPA-albumin-
RhoB at t = 35 min (after cardiac MRI) displaying vessel permeability in healthy, saline infarcts and UPyGF-
hydrogel injected infarcts at day 22 after I/R. Merged images with blue: nuclear staining with DAPI, green: 
albumin-GFP and red: GdDTPA-albumin-RhoB. (c) Collagen volume fraction (n = 8 for healthy, n = 4 for 
day 22 Saline, n = 5 for day 22 UPyGF mice). (d) Correlation of histological collagen volume fraction and MR-
based T1 mapping (R2 and P based on n = 17). (e) Albumin t = 4 min showing microvascular density (% area; 
n = 10 for healthy, n = 4 for day 22 Saline, n = 6 for day 22 UPyGF mice). (f) Correlation of fluorescence albumin 
t = 4 min and MR-based fractional blood volume (R2 and P based on n = 20). (g) Extravasated albumin showing 
permeability (% area; n = 10 for healthy, n = 4 for day 22 Saline, n = 6 for day 22 UPyGF mice). (h) Correlation of 
fluorescence extravasated albumin and MR-based permeability*Surface Area (R2 and P based on n = 20). Each 
dot represents an individual mouse; bars represent mean ± s.e.m.; One-way ANOVA with Kruskal-Wallis post-
hoc test; *P < 0.05, **P < 0.01, ****P < 0.0001.
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Discussion
In this study, we describe two advances: (1) a noninvasive multiparametric cardiac MRI tool aimed to characterize 
key regenerative processes after I/R injury; we established a unique triple-marker MRI approach assessing micro-
vascular features, fibrosis and regional muscle strain at different time points of cardiac healing following hydrogel 
delivery. (2) Our noninvasive multiparametric MRI approach demonstrated the therapeutic effects of a VEGF/
IGF1-loaded UPyGF-hydrogel after I/R injury by highlighting (i) the enhanced angiogenesis by fractional blood 
volume (fBV) and permeability * surface area product (PS), (ii) improved resolution of fibrosis by T1-mapping 
and (iii) elevated mechanical support as well as (re)muscularization by strain analysis of infarcted murine hearts 
(Fig. 8). Both claims are supported by gold standard ex vivo immunohistochemical analysis displaying an excel-
lent correlation of angiogenic and fibrotic MRI findings, showing the potential of this translational triple-marker 
MRI approach.
As the search for a novel and effective therapy to prevent the progression of post-MI heart failure continues, 
we tested a supramolecular UPyGF-hydrogel loaded with VEGF/IGF1. Optimally, time-to-treatment should be 
at the earliest possible time after ischemic injury. The injection of the UPyGF-hydrogel before reperfusion was 
intended to prevent damage from the oxidative stress of the reperfusion injury with release of oxygen-related 
free radicals29–31. The UPyGF-hydrogel prevented initial damage by providing a mechanical support in the tissue 
after injection that protects the injured myocardium in a high shear environment14. Furthermore, growth factor 
release from the UPyGF-hydrogel peaked at day 2–3 after injection (Fig. 1a), which is an ideal timing to initiate 
angiogenesis, as the revascularization is initiated at day 3 after I/R injury29,31. Despite our promising preclinical 
results and the fact that the delivery at time of reperfusion seems clinically optimal, future studies should examine 
the optimal time frame for treatment, both in clinical outcomes and patient burden.
Although stem cell therapy for cardiac repair and regeneration holds promising therapeutic potential, its benefi-
cial effect has been greatly attributed to the release of growth factors, such as VEGF and IGF1, acting in a paracrine 
fashion on resident cells4,32. IGF1 has been extensively studied to treat the heart after MI as it counteracts adverse 
cardiac remodeling working directly on cardiomyocytes and inflammatory cells; reduced apoptosis33,34, cardio-
protective effects against oxidative stress-dependent cell death35 and modulation of the inflammatory response8 at 
the infarcted area are possible underlying mechanisms. IGF1 works through receptor binding and intracellularly 
activates the protein kinase B pathway, stimulating cell growth and proliferation, and inhibiting apoptosis6–8.
VEGF, a cytokine that initiates the formation of new vessels, has been broadly examined as a treatment 
option to prevent heart failure after MI, as it also exerts cytoprotection, tissue regeneration, and neurohormonal 
effects5. VEGF works through receptor activation and molecular mediators resulting in inhibition of apoptosis by 
caspase-9 phosphorylation, vasodilation promoted through eNOS (endothelial nitric oxide synthase) activation 
with nitric oxide production, and activation of kinases inducing cellular proliferation, adhesion and migration. 
In vivo evidence has suggested that VEGF works both on local cells of the cardiac niche (e.i. stromal cells), as well 
as on the recruitment of distant bone marrow-derived cells (e.i. hematopoietic stem cells, monocytes), starting 
from cellular release, followed by cell migration, adhesion and, finally, diapedesis towards the damaged tissue5.
One of the major limitations for the therapeutic use of both VEGF and IGF1 is the very short half life following 
injection5,36. Entrapment of these growth factors in an engineered degradable hydrogel overcomes this limitation 
enabling prolonged release of VEGF and IGF1 over 7 days during the phase of active cardiac healing3. The burst 
release of VEGF was slower than IGF1. Previously published data have shown similar burst release for VEGF37 
and IGF114. However, the reason for discrepancy in burst release between VEGF and IGF1 has not been further 
explored. Possible explanations are partial degradation of VEGF hindering ELISA detection38 or difference in size 
Figure 8. Longitudinal multiparametric cardiac MRI comparing saline and UPyGF-hydrogel injected 
myocardial healing. Sequential tissue changes by saline and UPyGF-hydrogel injections to the infarcted hearts 
at 3 and 22 days after I/R comparing injection normalized to mean values of healthy myocardium. (fBV: 
fractional blood volume; PS: permeability*surface area product; T1: T1 relaxation time; Err: radial strain; Ecc: 
circumferential strain).
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between VEGF (39 kDa) and IGF-1 (7.6 kDa)39. The correct intramyocardial injection was imaged by incorpo-
rating USPIOs to the UPyGF-hydrogel. The very short T2* of the injected USPIOs created a susceptibility artifact, 
slightly overestimating the injected hydrogel area. Because of this, the hearts were isolated and placed in a tube, 
so the effective intramyocardial placement of the engineered hydrogel could be verified. These in vitro and ex 
vivo data demonstrated feasibility of the UPyGF-hydrogel as an intramyocardial carrier system in murine hearts. 
For porcine hearts, minimally invasive delivery of a UPy-hydrogel loaded with Gd through a catheter has been 
shown, emphasizing the translational potential of the gel15.
The continuous search to lower mortality after MI also demands methods to assess the risks of developing 
adverse cardiovascular events. Risk stratification is crucial for decision-making in existing treatment options, 
such as revascularization, as well as robustly evaluating novel regenerative therapies to prevent progression to 
post-MI heart failure. LV ejection fraction (≤30%) has become a primary method for stratifying risk like antici-
pating sudden cardiac death40. Yet, even patients with LV EF >30% may still suffer sudden cardiac death and this 
method does not provide any insights on aspects of cardiac healing40. The evaluation of myocardial tissue changes 
post-MI can deliver a patient-specific risk stratification, ultimately contributing to personalized medicine.
Cardiac MRI has emerged as a leading imaging modality assessing various components of post-MI myocar-
dium for risk assessment and personalized therapeutic decision making. Until now, measuring infarct size by LGE 
MRI has been a very strong predictor of mortality and heart failure41. Our study revealed that both the saline and 
UPyGF-hydrogel treated hearts had similar infarct size upon LGE MRI at day 1 after MI, meaning similar initial 
risk for developing adverse cardiovascular events. A mouse model of I/R injury with small infarct sizes was used 
to mimic clinical conditions28,42.
Cardiovascular albumin-based DCE MRI is a promising method to evaluate functional vascular features such 
as vascular density and permeability in mice19,20 and man43,44. Serial imaging showed that UPyGF-hydrogel therapy 
elevated the infarct fBV, a measure for microvascular density at day 3 and day 22 after I/R injury. Vascular perme-
ability (PS) was not significantly different at day 3 post-MI. As permeability early after MI correlated with leuko-
cyte transmigration, this indicated indirectly that the inflammatory reaction was not enhanced early post-MI20. 
PS appeared only significant in UPyGF-hydrogel treated mice late (day 22) after I/R injury. As permeability is a 
major indicator for angiogenesis45, this may indicate that angiogenesis was still ongoing at day 22 post-MI in the 
infarcted myocardium by prolonged release of VEGF from the UPyGF-hydrogel.
Furthermore, MR-based T1-mapping assessing fibrosis has been shown to be a promising method for 
risk evaluation both preclinically24,46 and clinically21,22. Our results showed that intramyocardial injection of 
UPyGF-hydrogel alleviated myocardial fibrosis at day 3 and day 22 post-MI. These findings were confirmed by 
histomorphometric analysis.
Global strain has recently been shown to have incremental prognostic value for mortality superior to LV 
ejection fraction and infarct size47,48. To include both intramycardial injection sites of saline or UPyGF-hydrogel, 
we chose to assess midventricular Ecc and Err strain serially by tagging MRI23. However, the use of tagging MRI 
for strain assessment resulted in the exclusion of multiple later timepoints due to tagging fading49. Other strain 
assessment approaches, such as feature tracking, might result in less exclusion of images, but have a risk of unre-
alistic results with local stain variations as we expected in MI23. Therefore tagging MRI is still the gold standard 
to rely on. We found compromised strain values for the saline injected group, whereas the strain values of the 
UPyGF-hydrogel treated group remained similar to healthy strain values. This is likely due to the initial mechan-
ical support of the UPy-hydrogel combined with the sustained release of growth factors to enhance survival of 
cardiomyocytes34.
In addition to classical MR assessment of infarct size by LGE MRI and LV global function by cine MRI post-
infarct, each separate MRI method, i.e. DCE MRI19, T1 mapping22 and tagging MRI23, has proven potential addi-
tional value for assessing distinct biomarkers of risk prediction after MI. Yet this combined triple-marker MR 
imaging method gives clear insights on post-MI tissue changes in one imaging session, allowing spatial and tem-
poral comparison of the therapeutic effects of the UPyGF-hydrogel. Other multi-biomarker studies have included 
simultaneous measurement of multiple tissue properties in a single acquisition measuring T1, T2 and T2*50,51. 
However, these measurements cannot provide functional data on regional muscle deformation or endothelial 
barrier function of the heart. Some studies have used cardiac positron emission tomography (PET)/MRI to assess 
cardiac inflammatory reactions, in addition to standard LGE, T1 and T2 MRI measurements52. Although PET is 
highly sensitive, for human applications MRI is favored as it is more widely available, nonradioactive, independ-
ent of cyclotron access, and cheaper.
This serial cardiac MRI strategy achieved (i) 3D characterization of vascular features showing increased 
microvascular density (fBV) and vascular permeability (PS) by DCE-MRI, (ii) MR-based evaluation of myocar-
dial fibrosis picturing improved T1 values of fibrosis and (iii) MR-based radial and circumferential strain analysis 
displaying enhanced regional wall motion in UPyGF-hydrogel treated infarcts. Improved global LV function was 
attributed to increased angiogenesis, enhanced resolution of fibrosis and elevated mechanical support as well 
as (re)muscularization in infarcted hearts treated with UPyGF-hydrogel. We envision that such multiparametric 
platforms will enable simultaneous studies of hallmarks for cardiac regeneration, at high resolution, to improve 
insights into the efficacy of novel regenerative cardiac therapies. Ultimately, this integrated in vivo MRI tool, can 
be translated clinically to provide longitudinal information of the regenerative aspects of novel cardiac therapies 
after MI.
Methods
Statement. All experiments and methods were performed in accordance with relevant guidelines and regu-
lations. All mouse procedures were approved by Maastricht University Animal Care Committee, The Netherlands 
(DEC2014–053).
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Synthesis and characteristics of UpyGf-hydrogel. Based on the fourfold hydrogen bonding supramo-
lecular ureido-pyrimidinone units were coupled with alkyl-urea to 10k poly(ethylene glycol) to synthesize the 
UPy-hydrogel (SyMO-Chem BV, Eindhoven, The Netherlands)14. A 10 wt% UPy-hydrogel was made by dissolv-
ing 10 wt% UPy-PEG in 90 wt% saline to a final pH 9. After one hour of stirring, the liquefied UPy-hydrogel was 
mixed with mouse recombinant VEGF and IGF1 (V4512–5UG and I8779–50UG, Sigma-Aldrich, St Louis, MO, 
USA) to a concentration of 500 ng/ml of both GF. In addition, a second batch of the UPyGF-hydrogel was mixed 
with 13,6 μg/ml USPIOS (Sinerem, Guerbet, Villepoint, France) for in vivo tracking after delivery. To assess the 
cumulative release of IGF1 and VEGF, 100 μl of the liquefied UPy-hydrogel was placed in a pipette at 24-well plate 
millicell hanging culture inserts (PIEP12R48, polyethylene terephtalate, 8.0μm; Merck Millipore, Darmstadt, 
Germany) and solidified by decreasing to pH 6.5 while adding hydrochloric acid. The MilliPores where sur-
rounded with 800 μl phosphate-buffers saline (PBS) and placed at a rotational shaker (100 rpm) at 37 °C for 7 days. 
The PBS surrounding the inserts was refreshed daily and the collected supernatant was quantified for VEGF and 
IGF1 by enzyme-linked immunosorbent assay detection (Mouse IGF1 ELISA Kit and Mouse VEGF ELISA Kit, 
Sigma-Aldrich, St Louis, USA).
Mice. Male outbred 12 ± 1weeks old OF1 mice (n = 35) were purchased from Charles River. A first batch of 
n = 14 healthy mice were used for implementation of cardiac MRI, and subsequent histological analysis. A second 
batch of n = 20 healthy mice were imaged prior to infarct induction and were randomly assigned to the saline 
injected (n = 11) or UPyGF-hydrogel injected (n = 9) group during I/R injury for serial cardiac MRI and histology 
at day 22 post infarction. To localize USPIO-loaded UPyGF-hydrogel after I/R injury by ex vivo MRI n = 1 mouse 
was used as a proof-of-concept. For induction of I/R surgery and in vivo cardiac MRI, anesthesia of the mice 
was induced with 4% isoflurane in 0.3 L/min oxygen and maintained with 1–2% isoflurane. During anesthesia, 
the body temperature was monitored with rectal thermometry and maintained at 35.5 ± 0.5 °C using a heating 
system. All mouse procedures were approved by Maastricht University Animal Care Committee, Netherlands.
Myocardial I/R injury model. A well-established left anterior descending (LAD) coronary artery ligation 
model was used26,42. In short, mice were anesthetized, endotracheally intubated and mechanically ventilated 
(Harvard Apparatus). Surgery was performed under an Olympus microscope. After thoracotomy, a 30 min liga-
tion of the LAD coronary artery was performed with a 8–0 monofilament suture and a PE-10 tube placed between 
the LAD coronary artery and the suture to protect the vessel from injury. Although there is still some controversy 
about the ideal timing of injection after MI, we have well considered several options taking into account the 
nature of our regenerative therapy and its dynamics. The most favorable time-to-treatment should be as early 
as possible after ischemic injury to prevent damage29–31. Two minutes prior to reperfusion, two intramyocardial 
injections of 10 μl saline or 10 μl UPyGF-hydrogel were placed on both sides of the ischemic area (Fig. 1c) by a 
90 degrees curved needle (0.3 mL U-100 insulin syringe, 29-gauge, BD Bioscience). At the end of the ischemic 
period, the LAD coronary artery ligation was removed and reperfusion of the LV was visually verified. Before 
and every 12 h until 72 h after the surgery, mice received buprenophine (0.05 mg/kg, SC) injections as analgesia. 
During the first 24 h after surgery, mice were kept in a recovery unit at 28 °C.
Cardiac MRI acquisition. A 9.4 T horizontal MRI scanner with 72-mm-diameter volume transmit coil with 
a four-element mouse cardiac phased-array surface receive coil (Bruker, Ettlingen, Germany) was used to per-
form all MRI experiments.
Ex vivo MRI protocol. Hearts were harvested 30 min after I/R injury and isolated to verify the intramyocardial 
localization of USPIO-loaded UPyGF-hydrogel. The pericardium was removed and the hearts were fixated in 
paraformaldehyde (polyoxymethylene, P6148, Sigma-Aldrich, St Louis, USA) in an Eppendorf tube. This tube 
was positioned in the isocenter of the magnet and imaged by T2*-weighted imaging performed with a standard 
gradient echo sequence using a thickness of 0.5 mm in long axis (20 slices) and short axis (25 slices) covering the 
whole heart. Following parameters were used: TE = 7 ms; flip angle = 30°; TR = 3355 ms; TEacq = 10.9 ms; spec-
tral width = 407 Hz; FOVlong axis = 40 × 40 mm; FOVshort axis 30 × 30 mm2; Nx × Ny = 192 × 192 with zero filling to 
256 × 256; acquisition time = 10m44s232ms.
In vivo MRI protocol. ECG electrodes were placed at the front paws to monitor the heart rate, which was main-
tained at 400–600 bpm by adjusting the isoflurane level. A respiratory sensor balloon was placed on the abdomen 
and the respiratory rate was kept at 70 ± 10 bpm (SA Instruments Model 1025, Stony Brook, NY, USA). The 
mouse was placed in the magnet so that the heart was positioned at the isocenter of the magnet in the middle of 
the phased array coil. Retrospective triggering was used to distinguish cardiac and respiratory phases from the 
images after acquisition. For healthy baseline and mice at days 3 and 21 after I/R, one imaging session accounted 
for DCE, T1-mapping, tagging and volumetric Cardiac MRI (5–7 days prior to I/R surgery). For day 1 after I/R 
injury, the imaging session was minimized to only tagging and LGE MRI, to diminish the time under anesthesia 
and to consequently optimize survival. At day 3 and 22 after I/R, DCE, T1-mapping, tagging and volumetric MRI 
were performed again (Fig. 1e).
Cardiac DCE MRI with precontrast T1-mapping. Prior to administration of the contrast agent, T1-weighted 
stacks of 2D fast low‐angle shot (FLASH) images covering the whole heart were acquired with a series of 
variable flip angles (2°, 5°, 8°, 11°, 13°) to determine the endogenous precontrast T1 as described in previous 
research19,24. In short, a retrospectively triggered FLASH sequence with constant TR was used with variable 
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flip angles. An indwelling tail catheter was used to intravenously inject 150 μl (100 mg/ml) macromolecular 
bovine serum albumin labeled with gadolinium diethylenetriaminepentacetate (GdDTPA) and rhodamine 
B (GdDTPA-albumin-RhoB, 82 kDa, SyMo-Chem, Eindhoven, The Netherlands) at a rate of 50 μl/min19. 
Immediately after administration of the contrast agent a dynamic series of images was acquired with a flip angle 
of 13° to determine post contrast T1 over time for quantification of contrast accumulation. Other imaging param-
eters were: TR = 10 ms; TE = 1.784 ms; n of repetitions = 22; FOV = 30 × 30; slice thickness = 10 mm; spec-
tral bandwidth = 100,000 Hz; Nx × Ny = 128 × 64 with zerofilling to 128 × 128 ; number of slices = 15; cardiac 
frames = 6; acquisition time = 4m1s200ms.
Tagging MRI. Midventricular tagged MRI images were obtained by preceding a 2D-FLASH sequence with 
a SPAMM preparation step applying a tagging grid with following parameters: distance = 0.5 mm; thick-
ness = 0.25 mm; angle = 45°; delay = 1.4 ms. These short axis tagged MRI images were positioned between the 
base and apex of the heart, containing the UPyGF-hydrogel or saline injection site. This sequence was prospectively 
gated and respiratory triggered per phase step with a trigger delay of 1 ms. The tagging was applied prior to the 
systolic phase and acquired images were ordered from the systolic to the diastolic phase (Supplementary Movie 1). 
Other imaging parameters were: α = 13°; TR = 15 ms; TE = 2.549 ms; FOV = 30 × 30 mm; Nx × Ny = 256 × 128 
with zerofilling to 256 × 256; cardiac frames = 16; acquisition time depends on cardiac triggering efficiency. 
Tagging series of insufficient image quality to assess tagging grid deformations49 because of tagging grid fading 
were excluded from analysis.
Cardiac Volumetric MRI. A retrospectively gated FLASH sequence (Intragate, Bruker, Ettingen, Germany) 
was applied to acquire cine images of the long axis orientation and determine the position of the short axis 
DCE MRI or the LGE MRI. The following parameters were used: α = 10°; TR = 8 ms; TE = 3 ms; n of repeti-
tions = 200; FOV = 30 × 30 mm; Nx × Ny = 192 × 192 with zerofilling to 256 × 256; slice thickness = 1 mm; car-
diac frames = 15; acquisition time = 5m9s200ms.
LGE MRI. One day after surgery the infarct size was determined by LGE MRI with an increased flip angle 
preparation step before a T1-weigthed 3D-FLASH sequence. The LGE MRI images were acquired 20 min after 
100 μl gadoterol (GdDTPA, 0.015 mmol/kg, Prohance, Bracco Diagnostics Inc.) was injected intravenously via an 
indwelling tail vein catheter at the same rate as above. The applied imaging parameters were: α = 30°; TR = 10 ms; 
TE = 1.784 ms; n of repetitions = 50; FOV = 30 × 30; slice thickeness = 10 mm; spectral width = 100,000 Hz; 
Nx × Ny = 128 × 64 with zerofilling to 128 × 128; number of slices = 15; cardiac frames = 6; acquisition 
time = 8m30s0ms.
Cardiac MRI data analysis. T1, fBV and PS. Cardiac T1-mapping and DCE MRI data analysis was done 
with Matlab (MathWorks Inc., USA). GdDTPA-albumin-RhoB concentrations were derived from the cardiac 



















where I is the signal intensity as a function of the pulse flip angle α, TR is the repetition time and the pre‐expo-
nent term M0 includes the spin density and T2 relaxation effects, assumed to be unaffected by the contrast agent. 
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Lastly, concentrations of the contrast agent were derived from the measured relaxivity (R) of 
GdDTPA-albumin-RhoB (R = 130 mM−1s−1 at 9.4 T; Eq. 3):
− − = −GdDTPA albumin RhoB
R
[ ] 1 (R1post R1pre) (3)
Regions of interest (ROIs) for T1, fBV and PS were defined as healthy before I/R injury for the entire myocar-
dium and as infarcted for a hyper intense infarct region defined by LGE MRI images. From the temporal changes 
in these normalized concentrations fBV and PS were quantified. First, fBV was derived from the extrapolation 
of a linear regression of the normalized concentrations to the time of administration of the contrast. Second, the 
slope of these normalized concentration values (Fig. 1b), the rate of normalized concentration increase or PS 
(min−1), was derived from a linear regression of the normalized concentrations over time. The PS quantified with 
GdDTPA-albumin-RhoB exhibited the extravasation of albumin from blood vessels and its accumulation in the 
tissue. Cardiac parametric T1, fBV and PS maps were projected to indicate the mean value in each pixel.
Strain. Strain calculations were done by using Wolfram Mathematica v10 based software, adapted from pre-
vious research25. The method obtained the circumferential (Ecc) and radial (Err) strains from the tagging MRI 
data (Fig. 2e–g) and is based on local tagging frequency estimations described elsewhere25,53. Briefly, the Gabor 
transform was applied to construct a local frequency representation of the tagging images A Gaussian filter was 
used to calculate the Gabor transform in each pixel and a single spatial frequency covector ωt was extracted (t is 
the time frame of the MRI acquisition the covector was calculated from). Each ωt is related to its counterpart in 
the first frame ω0 for the same material point through the deformation tensor F Eq. 4):
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Where ωt and ω0 are are the frequencies of corresponding material points at different moments in time and F is 
the deformation tensor (Eq. 5). It is assumed that at the moment of applying the tagging grid t0, which is before 
acquisition of the image, the tag frequency is known and and equal for all material points. To be able to solve for 
F, frequency-matrices Ωt and Ω0 are derived by combining frequency covectors ωt and ω0 for multiple tagging 
directions extracted tagged images:





Here ΩT is the transpose of Ω. From this the Lagrangian strain tensor (Eq. 6) is defined as followed:




Where I is an unit tensor. From the 2 × 2-tensor E the Err and Ecc strains can be extracted. Prior to these strain 
calculations the endocardial and epicardial borders were manually drawn into the image slices to limit the defor-
mation analysis to that area. The peak Err and Ecc were calculated in the whole LV (Fig. 2f) and were analyzed 
by dividing the LV into 12 segments in the circumferential direction and two in the radial direction, which is a 
refinement of the American Heart Association (AHA) model. The peak strains of the infarct area segments were 
compared between the saline and UPyGF-hydrogel groups. For healthy controls the same segments were used. For 
regional strain analysis, the accuracy of tagging MRI is known to be dependent on the image quality54. Our data 
suffered from tag fading, especially in the diastolic phase, which is a known problem for this technique49 mak-
ing it impossible to accurately analyze some datasets. Datasets with excessive tagging grid fading were excluded 
(Supplementary Fig. 1), which explains the lower number of animals for regional strain analysis than T1, fBV and 
PS analysis.
Infarct size, EF. To gain insights into the effect of the UPyGF-hydrogel therapy in the heart, infarct size and global 
LV function were calculated with Segment v1.9 R3819 software (http://segment.heiberg.se). At day 1 postinfarc-
tion, 3D LGE MRI images were used to determine infarct sizes of the different saline and UPyGF-hydrogel injected 
LVs. The infarct areas were defined from pixels with a signal intensity of more than 3 standard deviations above 
the mean signal intensity of the remote area (Fig. 3a). The precontrast 3D FLASH images with 13° flip angle from 
the healthy control and day 3 and 22 for the saline and UPyGF-hydrogel groups were used to determine the LV EF. 
Segment v1.9 R3819 software was used to manually draw the endocardial and epicardial borders in the short axis 
images and automatically calculated the EF from the difference in LVEDV and LVESV divided by the LVEDV.
Histological analysis. Ex vivo histology preparation. After the MRI experiment (healthy and at day 22 after 
infarction), 150 μl fluorescein isothiocyanate labeled BSA (FITC-albumin, 100 mg/ml) was intravenously injected 
via the indwelling catheter as an early albumin marker to confirm MR-based fBV. Mice were sacrificed 4 min after 
FITC-albumin and 35 min after GdDTPA-albumin-RhoB injection by cervical dislocation while anesthetized. 
The hearts were isolated, rinsed and fixed in paraformaldehyde. Afterwards, the hearts were mounted on OCT 
embedding compound (Fisher Scientific, Hampton, NH, USA) and frozen at −80 °C. Hearts were cryosectioned 
at 7 μm through the short axis at −35 °C.
Collagen content. For Picrosirius Red staining of collagen, 3–4 sections per heart were incubated with 0.1% 
Sirius Red (Direct Red 80, Sigma-Aldrich, St Louis, USA). Sections were visualized with identical exposure set-
tings in a light microscope (3DHistech microscope, Budapest, Hungary). The interstitial collagen fraction (dark 
red) was determined by quantitative morphometry of the picrosirius-stained sections with with ImageJ software. 
The density of labeled areas was measured from 3 randomly selected fields of each section at a x10 magnification. 
The expressed value was the ratio of the dark red collagen area to total area.
Fluorescent albumin quantification. In adjacent section, nuclei where stained in blue with 
4′,6-diamidino-2-phenylindole (DAPI, D9542, Sigma-Aldrich, St Louis, USA). To visualize fluorescence of 
FITC-albumin injected for 4 min, GdDTPA-albumin-RhoB injected for 35 min, and DAPI, 3–4 slices were 
imaged with identical exposure times (3DHistech microscope, CMOS camera). The density of labeled areas was 
qualitatively estimated from 3 randomly selected fields of each section at a x20 magnification. The % area of 
FITC-albumin (4 min) was the ratio of the green fluorescence area to total area. Subtraction of this fraction from 
the red fluorescent fraction (GdDTPA-albumin-RhoB; 35 min injected) provided the contrast leakage from the 
vasculature and therefore an estimation for the permeability. All fluorescent images were analyzed with imageJ 
software.
Statistics. Statistical analysis was performed using GraphPad Prism (version 8.00; GraphPad, San Diego, 
CA). Normality was checked by the Shapiro–Wilk test. Differences between not normal distributed groups 
were analyzed for statistical significance with the parametric Mann-Whitney U test. Multiple comparisons were 
corrected for statistical significance with the Bonferroni-Dunn method. For histology, three groups were com-
pared using a one-way ANOVA with Kruskal-Wallis post-hoc test. To assess correlation between two variables, 
Pearson’s R2 and two-tailed P value were computed. Data are presented as mean ± SEM and a P value of ≤0.05 
was considered significant.
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